← FDA DRUG APPROVALS

FDA NDA · NDA209949

DAPTOMYCIN

Sponsor: HIKMA

APPLICATION
NDA209949
TYPE
NDA
ORIGINAL APPROVAL
2017-10-20
LATEST ACTION
2025-04-30
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

DAPTOMYCIN · ReferencePrescription
DAPTOMYCIN 350MG/VIAL · POWDER · INTRAVENOUS

Approval history

2025-04-30Labeling · Supplement 14 · standard — Letter ↗AP
2023-10-06Labeling · Supplement 11 · standard — Letter ↗AP
2021-05-05Efficacy · Supplement 7 · standard — Label ↗AP
2021-05-05Efficacy · Supplement 6 · standard — Letter ↗AP
2019-09-18Labeling · Supplement 3 · standard — Label ↗AP
2017-10-20Type 5 - New Formulation or New Manufacturer · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →